Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05512494
Other study ID # PRO-QINF-4003
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 27, 2022
Est. completion date January 24, 2023

Study information

Verified date July 2022
Source Sinovac Biotech Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a randomized, double-blind phase Ⅳ clinical trial of quadrivalent influenza vaccine (Split Virion), inactivated manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the lot-to-lot consistency, immunogenicity and safety of quadrivalent influenza vaccine (Split Virion), inactivated in health subjects aged 9-59 years old.


Description:

This study is a randomized, double-blind phase Ⅳ clinical trial in health subjects aged 9-59 years old to evaluate the lot-to-lot consistency,immunogenicity and safety of quadrivalent influenza vaccine (Split Virion), inactivated.The experimental vaccine was manufactured by Sinovac Biotech Co., Ltd.A total of 1260 subjects,including 360 subjects aged 9-17 years and 900 subjects aged 18-59 years will be enrolled.The subjects in each age group will be randomly divided into three groups in a ratio of 1:1:1 to receive one dose of three lots of quadrivalent influenza vaccine (Split Virion), inactivated produced on a commercial scale,respectively.


Recruitment information / eligibility

Status Completed
Enrollment 1260
Est. completion date January 24, 2023
Est. primary completion date January 24, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 9 Years to 59 Years
Eligibility Inclusion Criteria: - Healthy subjects aged 9-59 years; - The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 9-17 years, both subjects and guardians need to sign the informed consent form). - Proven legal identity. Exclusion Criteria: - Received seasonal influenza vaccine for 2022-2023 influenza season, or had an influenza vaccine schedule during the study; - Suffering from seasonal influenza in the past 6 moths; - Women of childbearing age (menarche to premenopause) are pregnant(including positive urine pregnancy test), breastfeeding or planning pregnancy within 1 month; - Patients with fever on the day of vaccination,underarm body temperature>37.2 ?; - History of asthma, allergy to vaccines or vaccine components, and serious adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema; - Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. - Severe chronic diseases,such as severe cardiovascular diseases, hypertension(Systolic blood pressure =140mmHg and/or diastolic blood pressure =90mmHg) and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.; - Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; - Autoimmune disease or immune deficiency/immunosuppression; - Thyroid disease or history of thyroidectomy,absence of spleen, functional functional asplenia,and absence of spleen or splenectomy as a result of any condition; - Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; - Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months; - A long history of alcohol or drug abuse; - Onset of various acute or chronic diseases within 7 days prior to the study; - Receipt of blood products within in the past 3 months; - Receipt of other investigational drugs within 30 days prior to receiving the investigational vaccine; - Receipt of attenuated live vaccines or COVID-19 vaccines in the past 14 days,receipt of inactivated or subunit vaccines in the past 7 days; - The subjects participated in other clinical trials during the follow-up period or will be planned to participate other clinical trials during the follow-up period; - According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Quadrivalent Influenza Vaccine (Split Virion), inactivated
The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. The four influenza strains(including 4 antigens H1N1, H3N2, BV and BY, 15µg for each) in 0.5 mL of sodium chloride,disodium hydrogen phosphate,sodium dihydrogen phosphate water for per injection.The routine of administration is intramuscular injection into deltoid region.And the immunization schedule is one dose of quadrivalent influenza vaccine on day 0.

Locations

Country Name City State
China Yuping Dong Autonomous County Center for Disease Control and Prevention Zhumadian Guizhou

Sponsors (1)

Lead Sponsor Collaborator
Sinovac Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunogenicity index of GMT GMT of HI antibodies of each influenza strain at 28 days after vaccination. 28 days after vaccination
Secondary Immunogenicity index of seroconversion rate Seroconversion rate of HI antibodies of each influenza strain at 28 days after vaccination. 28 days after vaccination
Secondary Immunogenicity index of protection rate Protection rate of HI antibodies of each influenza strain at 28 days after vaccination (HI antibody titer =1:40). 28 days after vaccination
Secondary Immunogenicity index of GMI GMI of HI antibodies of each influenza strain at 28 days after vaccination. 28 days after vaccination
Secondary Safety index of the incidence of adverse reactions Incidence of adverse reactions from 0 to 28 days after vaccination. From 0 to 28 days after vaccination.
Secondary Safety index -The incidence of adverse reactions Incidence of adverse reactions from 0 to 7 days after vaccination. From 0 to 7 days after vaccination.
Secondary Safety index of the incidence of serious adverse events Incidence of serious adverse events from 0 to 28 days after vaccination. From 0 to 28 days after vaccination
Secondary Safety index of incidence of adverse events Incidence of adverse events of special concern from 0 to 28 days after vaccination. From 0 to 28 days after vaccination
See also
  Status Clinical Trial Phase
Completed NCT01209780 - Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age Phase 3
Completed NCT01180621 - Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children Phase 2
Completed NCT01206686 - The Effect of Time-Slot Scheduling on Flu Vaccination Rates N/A
Recruiting NCT06049927 - A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months Phase 3
Completed NCT04133584 - The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine Phase 4
Completed NCT05566639 - A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older Phase 3
Completed NCT01207232 - The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates N/A
Completed NCT00957996 - Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Phase 3
Completed NCT01072799 - Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine Phase 2
Completed NCT04997239 - A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old Phase 4
Completed NCT01011582 - Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza N/A
Terminated NCT00958776 - A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza Phase 3
Completed NCT00560066 - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions Phase 4
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT04896086 - First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults Phase 1
Completed NCT01344057 - Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 Phase 2
Completed NCT01342796 - Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Phase 2
Completed NCT00903552 - Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) Phase 2
Completed NCT05827068 - A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults Phase 1/Phase 2
Completed NCT05415462 - A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Phase 3